Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease

University of Arkansas at Little Rock, Little Rock, Arkansas, United States
British Journal of Haematology (Impact Factor: 4.71). 03/2007; 136(3):393-9. DOI: 10.1111/j.1365-2141.2006.06441.x
Source: PubMed


Complete response (CR) is still considered an important surrogate marker for outcome in multiple myeloma (MM). Long-term survival after transplantation, however, has been observed in a substantial proportion of patients who never achieved CR. The tandem transplant trial, Total Therapy 2, enrolled 668 patients, who were randomised up-front to thalidomide (THAL) or no THAL; 56 patients were identified as having had, for at least 6 months prior to initiation of therapy, monoclonal gammopathy of undetermined significance (MGUS, n = 21), smouldering MM (SMM, n = 22) or solitary plasmacytoma of bone (SPC, n = 13). The clinical characteristics and outcomes of patients with such 'evolved' MM (E-MM) and of those with 'unknown' prior history (U-MM) were compared. Fewer patients with MGUS/SMM-E-MM had anaemia or renal failure; CR was lower (22% vs. 48%) but 4-year estimates of event-free survival (54% vs. 56% with U-MM) and overall survival (65% vs. 70% with U-MM) were similar to those with SPC-E-MM or U-MM. In the latter group, achieving CR was associated with prolonged survival. In comparison with U-MM, E-MM evolved from MGUS/SMM was associated with lower CR rate without adversely affecting survival. In contrast, CR was an independent favourable feature for survival in U-MM.

Download full-text


Available from: Joshua Epstein, May 22, 2015
  • Source
    • "Figure 2C depicts the different levels of response by treatment phase. Among 16 variables evaluated for association with CR, positive correlations were observed with light chain only subtype [Hazard Ratio (HR) ¼ 4AE29, P < 0AE001], IgA isotype (HR ¼ 2AE60, P < 0AE001), GEP-defined PROLIFERATION subgroup (Zhan et al, 2006) (HR ¼ 1AE76, P ¼ 0AE05), high albumin ‡ 35 g/l (HR ¼ 1AE65, P ¼ 0AE019) and absence of documented prior history of monoclonal gammopathy of undetermined significance (MGUS) or smoldering MM (HR ¼ 7AE84, P ¼ 0AE040) (Pineda-Roman et al, 2007). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Total therapy 3 incorporated bortezomib into a melphalan-based tandem transplant regimen for 303 newly diagnosed patients with myeloma. Induction chemotherapy prior to and consolidation chemotherapy after transplants each consisted of two cycles of VTD-PACE (bortezomib, thalidomide, dexamethasone and 4-d continuous infusions of cis-platin, doxorubicin, cyclophosphamide, etoposide); 3-year maintenance comprised monthly cycles of VTD in the first and TD in the remaining years. The median age was 59 years (age >64 years, 28%). A minimum of 20 x 10(6) CD34 cells/kg was collected in 87% of patients; 83% completed both transplants, and only 5% suffered a treatment-related death. At 24 months, 83% had achieved near-complete remission, which was sustained in 88% at 2 years from its onset. With a median follow-up of 20 months, 2-year estimates of event-free and overall survival were 84% and 86% respectively. The 44 patients who experienced an event more often had a high-risk gene array profile, cytogenetic abnormalities and indicators of high lactate dehydrogenase, beta-2-microglobulin, creatinine and International Staging System stage. Toxicities of grade > 2 included thrombo-embolic events in 27% and peripheral neuropathy in 12%. Results of this phase-2 study demonstrated that bortezomib could be safely combined with multi-agent chemotherapy, effecting near-complete remission status and 2-year survival rates in more than 80% of patients.
    British Journal of Haematology 07/2007; 138(2):176-85. DOI:10.1111/j.1365-2141.2007.06639.x · 4.71 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The task of detection of specific buried objects in ground penetrating radar (GPR) images is considered. A modification of the Hough transform (HT) is proposed and applied to this problem. Methods of texture analysis are used to determine the soil structure. The possibility of gaining information about the material of the buried object is examined. The results of some experiments with GPR imagery are shown and discussed
    Geoscience and Remote Sensing Symposium, 1993. IGARSS '93. Better Understanding of Earth Environment., International; 09/1993
  • [Show abstract] [Hide abstract]
    ABSTRACT: This review details major new observations in the diagnosis and treatment of leukemias and plasma cell dyscrasias that have been communicated since the last version of this work. This review is not exhaustive and may appear to some to be rather superficial. However, it should serve as an accurate index of current thinking and accomplishments. The review clearly demonstrates a trend away from traditional chemotherapeutic approaches to the leukemias and related diseases in favor of the more rational design of treatments for specific diseases based on laboratory observations. Some refer to the agents that have resulted from such an approach as targeted therapy and suggest that they represent a new era in cancer treatment, although one of the first targeted therapy agents to be conceived, synthesized and tested was 6-mercaptopurine decades ago. Furthermore, there is no cancer therapy more targeted than surgery, which has been practiced longer than any of us has lived. At any rate, whatever slogan may be used to describe current cancer treatment, it is clear that it is based on more preclinical science and more rational design than ever before. This chapter demonstrates that is certainly true for the leukemias and plasma cell dyscrasias. What has not been demonstrated yet is that better rationale has led to better results. That remains to be proven or disproven by continued observation of our treated patients.
    Cancer chemotherapy and biological response modifiers 02/2005; 22(2):343-89. DOI:10.1016/j.uct.2006.05.007
Show more